AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GSK
  4. [6-K] GSK plc American Current Report (Foreign Issuer)

[6-K] GSK plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
GSK reported significant insider share purchases by multiple board members and executives on June 20, 2025. Key transactions include: Senior Independent Director Charles Bancroft purchased 2,021 ADSs at $37.8958 per share on NYSE, Lady Susan Symonds (PCA of Non-Executive Chair) acquired 1,350 ordinary shares at 拢14.3550 on LSE, and Independent Director Wendy Becker bought 545 ordinary shares at 拢14.3550. Multiple other directors including Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee, and Dr Vishal Sikka also made purchases of ADSs ranging from 257 to 889 shares at $37.8958 each. These coordinated insider purchases by board members could signal confidence in GSK's future prospects. All transactions were executed across LSE and NYSE, demonstrating global board participation in share accumulation.
GSK ha riportato importanti acquisti di azioni da parte di diversi membri del consiglio e dirigenti il 20 giugno 2025. Le transazioni principali includono: il Senior Independent Director Charles Bancroft ha acquistato 2.021 ADS a 37,8958 dollari per azione sul NYSE, Lady Susan Symonds (PCA del Presidente Non Esecutivo) ha acquisito 1.350 azioni ordinarie a 14,3550 sterline sulla LSE, e l'Independent Director Wendy Becker ha comprato 545 azioni ordinarie a 14,3550 sterline. Altri direttori, tra cui il Dr. Hal Barron, la Dr.ssa Anne Beal, il Dr. Hal Dietz, la Dr.ssa Jeannie Lee e il Dr. Vishal Sikka, hanno effettuato acquisti di ADS che variano da 257 a 889 azioni a 37,8958 dollari ciascuna. Questi acquisti coordinati da parte dei membri del consiglio potrebbero indicare fiducia nelle prospettive future di GSK. Tutte le transazioni sono state eseguite tra LSE e NYSE, dimostrando una partecipazione globale del consiglio nell'accumulo di azioni.
GSK inform贸 compras significativas de acciones por parte de varios miembros de la junta y ejecutivos el 20 de junio de 2025. Las transacciones clave incluyen: el Director Independiente Senior Charles Bancroft adquiri贸 2,021 ADS a 37.8958 d贸lares por acci贸n en la NYSE, Lady Susan Symonds (PCA del Presidente No Ejecutivo) compr贸 1,350 acciones ordinarias a 14.3550 libras en la LSE, y la Directora Independiente Wendy Becker adquiri贸 545 acciones ordinarias a 14.3550 libras. Varios otros directores, incluyendo al Dr. Hal Barron, la Dra. Anne Beal, el Dr. Hal Dietz, la Dra. Jeannie Lee y el Dr. Vishal Sikka, tambi茅n realizaron compras de ADS que van desde 257 hasta 889 acciones a 37.8958 d贸lares cada una. Estas compras coordinadas por parte de los miembros de la junta podr铆an indicar confianza en las perspectivas futuras de GSK. Todas las transacciones se ejecutaron en la LSE y NYSE, demostrando una participaci贸n global del consejo en la acumulaci贸n de acciones.
GSK電� 2025雲� 6鞗� 20鞚� 鞐煬 鞚挫偓須� 氅る矂 氚� 鞛勳洂霌れ潣 雽�攴滊 雮措秬鞛� 欤检嫕 毵れ瀰鞚� 氤搓碃頄堨姷雼堧嫟. 欤检殧 瓯半灅搿滊姅 靾橃劃 霃呺 鞚挫偓 彀办姢 氡呿伂搿滍攧韸戈皜 NYSE鞐愳劀 欤茧嫻 37.8958雼煬鞐� 2,021 ADS毳� 毵れ瀰頄堨溂氅�, 牍勳儊鞛� 鞚橃灔 PCA鞚� 霠堨澊霐� 靾橃灁 鞁滊歃堦皜 LSE鞐愳劀 欤茧嫻 14.3550韺岇毚霌滌棎 1,350 氤错喌欤茧ゼ 旆摑頄堦碃, 霃呺 鞚挫偓 鞗敂 氩犾护臧� 霃欖澕頃� 臧�瓴╈棎 545 氤错喌欤茧ゼ 毵れ瀰頄堨姷雼堧嫟. 霕愴暅 頃� 氚半煱 氚曥偓, 鞎� 牍勳柤 氚曥偓, 頃� 霐旍笭 氚曥偓, 歆�雼� 毽� 氚曥偓, 牍勳儸 鞁滌勾 氚曥偓 霌� 鞐煬 鞚挫偓霌れ澊 臧侁皝 257欤检棎靹� 889欤� 靷澊鞚� ADS毳� 欤茧嫻 37.8958雼煬鞐� 甑Г頄堨姷雼堧嫟. 鞚挫偓須� 氅る矂霌れ潣 鞚措煬頃� 順戨牓霅� 雮措秬鞛� 毵れ瀰鞚� GSK鞚� 氙鸽灅 鞝勲鞐� 雽�頃� 鞁犽毳� 雮橅儉雮� 靾� 鞛堨姷雼堧嫟. 氇摖 瓯半灅電� LSE鞕� NYSE鞐愳劀 鞚措（鞏挫牳 旮�搿滊矊 鞚挫偓須� 氅る矂霌れ潣 欤检嫕 於曥爜 彀胳棳毳� 氤挫棳欷嶋媹雼�.
GSK a annonc茅 des achats d'actions importants r茅alis茅s par plusieurs membres du conseil d'administration et cadres le 20 juin 2025. Les transactions cl茅s comprennent : Charles Bancroft, Directeur Ind茅pendant Senior, a achet茅 2 021 ADS 脿 37,8958 $ par action 脿 la NYSE, Lady Susan Symonds (PCA du Pr茅sident Non-Ex茅cutif) a acquis 1 350 actions ordinaires 脿 14,3550 拢 脿 la LSE, et Wendy Becker, Directrice Ind茅pendante, a achet茅 545 actions ordinaires au m锚me prix. Plusieurs autres administrateurs, dont le Dr Hal Barron, le Dr Anne Beal, le Dr Hal Dietz, le Dr Jeannie Lee et le Dr Vishal Sikka, ont 茅galement effectu茅 des achats d'ADS allant de 257 脿 889 actions 脿 37,8958 $ chacune. Ces achats coordonn茅s par les membres du conseil pourraient indiquer une confiance dans les perspectives futures de GSK. Toutes les transactions ont 茅t茅 r茅alis茅es sur la LSE et la NYSE, d茅montrant une participation mondiale du conseil dans l'accumulation d'actions.
GSK meldete am 20. Juni 2025 bedeutende Insider-Aktienk盲ufe mehrerer Vorstandsmitglieder und F眉hrungskr盲fte. Zu den wichtigsten Transaktionen z盲hlen: Senior Independent Director Charles Bancroft erwarb 2.021 ADS zu je 37,8958 USD an der NYSE, Lady Susan Symonds (PCA des Nicht-Exekutivvorsitzenden) kaufte 1.350 Stammaktien zu 14,3550 拢 an der LSE, und Independent Director Wendy Becker erwarb 545 Stammaktien zu 14,3550 拢. Weitere Direktoren, darunter Dr. Hal Barron, Dr. Anne Beal, Dr. Hal Dietz, Dr. Jeannie Lee und Dr. Vishal Sikka, t盲tigten ebenfalls K盲ufe von ADS in einer Spanne von 257 bis 889 Aktien zu je 37,8958 USD. Diese koordinierten Insider-K盲ufe durch Vorstandsmitglieder k枚nnten Vertrauen in die zuk眉nftigen Aussichten von GSK signalisieren. Alle Transaktionen wurden an der LSE und NYSE ausgef眉hrt, was eine globale Beteiligung des Vorstands an der Aktienakkumulation zeigt.
Positive
  • Multiple board members and insiders purchased shares on June 20, 2025, demonstrating confidence in the company's future direction
  • Senior Independent Non-Executive Director Charles Bancroft made the largest purchase of 2,021 ADSs at $37.8958 per share, representing a significant personal investment
  • Total insider buying activity includes both ordinary shares (1,895 shares) and ADSs (4,456 shares) across multiple board members
Negative
  • The relatively small purchase sizes by some directors (around 257-258 ADSs each) may indicate limited conviction levels
  • The timing of multiple coordinated purchases could suggest a planned buying program rather than spontaneous confidence in the stock
GSK ha riportato importanti acquisti di azioni da parte di diversi membri del consiglio e dirigenti il 20 giugno 2025. Le transazioni principali includono: il Senior Independent Director Charles Bancroft ha acquistato 2.021 ADS a 37,8958 dollari per azione sul NYSE, Lady Susan Symonds (PCA del Presidente Non Esecutivo) ha acquisito 1.350 azioni ordinarie a 14,3550 sterline sulla LSE, e l'Independent Director Wendy Becker ha comprato 545 azioni ordinarie a 14,3550 sterline. Altri direttori, tra cui il Dr. Hal Barron, la Dr.ssa Anne Beal, il Dr. Hal Dietz, la Dr.ssa Jeannie Lee e il Dr. Vishal Sikka, hanno effettuato acquisti di ADS che variano da 257 a 889 azioni a 37,8958 dollari ciascuna. Questi acquisti coordinati da parte dei membri del consiglio potrebbero indicare fiducia nelle prospettive future di GSK. Tutte le transazioni sono state eseguite tra LSE e NYSE, dimostrando una partecipazione globale del consiglio nell'accumulo di azioni.
GSK inform贸 compras significativas de acciones por parte de varios miembros de la junta y ejecutivos el 20 de junio de 2025. Las transacciones clave incluyen: el Director Independiente Senior Charles Bancroft adquiri贸 2,021 ADS a 37.8958 d贸lares por acci贸n en la NYSE, Lady Susan Symonds (PCA del Presidente No Ejecutivo) compr贸 1,350 acciones ordinarias a 14.3550 libras en la LSE, y la Directora Independiente Wendy Becker adquiri贸 545 acciones ordinarias a 14.3550 libras. Varios otros directores, incluyendo al Dr. Hal Barron, la Dra. Anne Beal, el Dr. Hal Dietz, la Dra. Jeannie Lee y el Dr. Vishal Sikka, tambi茅n realizaron compras de ADS que van desde 257 hasta 889 acciones a 37.8958 d贸lares cada una. Estas compras coordinadas por parte de los miembros de la junta podr铆an indicar confianza en las perspectivas futuras de GSK. Todas las transacciones se ejecutaron en la LSE y NYSE, demostrando una participaci贸n global del consejo en la acumulaci贸n de acciones.
GSK電� 2025雲� 6鞗� 20鞚� 鞐煬 鞚挫偓須� 氅る矂 氚� 鞛勳洂霌れ潣 雽�攴滊 雮措秬鞛� 欤检嫕 毵れ瀰鞚� 氤搓碃頄堨姷雼堧嫟. 欤检殧 瓯半灅搿滊姅 靾橃劃 霃呺 鞚挫偓 彀办姢 氡呿伂搿滍攧韸戈皜 NYSE鞐愳劀 欤茧嫻 37.8958雼煬鞐� 2,021 ADS毳� 毵れ瀰頄堨溂氅�, 牍勳儊鞛� 鞚橃灔 PCA鞚� 霠堨澊霐� 靾橃灁 鞁滊歃堦皜 LSE鞐愳劀 欤茧嫻 14.3550韺岇毚霌滌棎 1,350 氤错喌欤茧ゼ 旆摑頄堦碃, 霃呺 鞚挫偓 鞗敂 氩犾护臧� 霃欖澕頃� 臧�瓴╈棎 545 氤错喌欤茧ゼ 毵れ瀰頄堨姷雼堧嫟. 霕愴暅 頃� 氚半煱 氚曥偓, 鞎� 牍勳柤 氚曥偓, 頃� 霐旍笭 氚曥偓, 歆�雼� 毽� 氚曥偓, 牍勳儸 鞁滌勾 氚曥偓 霌� 鞐煬 鞚挫偓霌れ澊 臧侁皝 257欤检棎靹� 889欤� 靷澊鞚� ADS毳� 欤茧嫻 37.8958雼煬鞐� 甑Г頄堨姷雼堧嫟. 鞚挫偓須� 氅る矂霌れ潣 鞚措煬頃� 順戨牓霅� 雮措秬鞛� 毵れ瀰鞚� GSK鞚� 氙鸽灅 鞝勲鞐� 雽�頃� 鞁犽毳� 雮橅儉雮� 靾� 鞛堨姷雼堧嫟. 氇摖 瓯半灅電� LSE鞕� NYSE鞐愳劀 鞚措（鞏挫牳 旮�搿滊矊 鞚挫偓須� 氅る矂霌れ潣 欤检嫕 於曥爜 彀胳棳毳� 氤挫棳欷嶋媹雼�.
GSK a annonc茅 des achats d'actions importants r茅alis茅s par plusieurs membres du conseil d'administration et cadres le 20 juin 2025. Les transactions cl茅s comprennent : Charles Bancroft, Directeur Ind茅pendant Senior, a achet茅 2 021 ADS 脿 37,8958 $ par action 脿 la NYSE, Lady Susan Symonds (PCA du Pr茅sident Non-Ex茅cutif) a acquis 1 350 actions ordinaires 脿 14,3550 拢 脿 la LSE, et Wendy Becker, Directrice Ind茅pendante, a achet茅 545 actions ordinaires au m锚me prix. Plusieurs autres administrateurs, dont le Dr Hal Barron, le Dr Anne Beal, le Dr Hal Dietz, le Dr Jeannie Lee et le Dr Vishal Sikka, ont 茅galement effectu茅 des achats d'ADS allant de 257 脿 889 actions 脿 37,8958 $ chacune. Ces achats coordonn茅s par les membres du conseil pourraient indiquer une confiance dans les perspectives futures de GSK. Toutes les transactions ont 茅t茅 r茅alis茅es sur la LSE et la NYSE, d茅montrant une participation mondiale du conseil dans l'accumulation d'actions.
GSK meldete am 20. Juni 2025 bedeutende Insider-Aktienk盲ufe mehrerer Vorstandsmitglieder und F眉hrungskr盲fte. Zu den wichtigsten Transaktionen z盲hlen: Senior Independent Director Charles Bancroft erwarb 2.021 ADS zu je 37,8958 USD an der NYSE, Lady Susan Symonds (PCA des Nicht-Exekutivvorsitzenden) kaufte 1.350 Stammaktien zu 14,3550 拢 an der LSE, und Independent Director Wendy Becker erwarb 545 Stammaktien zu 14,3550 拢. Weitere Direktoren, darunter Dr. Hal Barron, Dr. Anne Beal, Dr. Hal Dietz, Dr. Jeannie Lee und Dr. Vishal Sikka, t盲tigten ebenfalls K盲ufe von ADS in einer Spanne von 257 bis 889 Aktien zu je 37,8958 USD. Diese koordinierten Insider-K盲ufe durch Vorstandsmitglieder k枚nnten Vertrauen in die zuk眉nftigen Aussichten von GSK signalisieren. Alle Transaktionen wurden an der LSE und NYSE ausgef眉hrt, was eine globale Beteiligung des Vorstands an der Aktienakkumulation zeigt.
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of June 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 
GSK plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Lady Susan Symonds
 
b)
Position/status
PCA of Sir Jonathan Symonds (Non-Executive Chair)
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Purchase of 1,350 Ordinary Shares
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.3550
 
1,350
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Wendy Becker
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Purchase of 545 Ordinary Shares
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.3550
 
545
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Elizabeth (Liz) McKee Anderson
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 258 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
258
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Charles Bancroft
 
b)
Position/status
Senior Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 2,021 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
2,021
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Hal Barron
 
b)
Position/status
Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 258 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
258
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Anne Beal
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 257 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
257
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Hal Dietz
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 257 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
257
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Jeannie Lee
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 258 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
258
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr Vishal Sikka
 
b)
Position/status
Independent Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W2044
 
b)
Nature of the transaction
Purchase of 889 ADSs
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$37.8958
 
889
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2025-06-20
 
f)
Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: June 23, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

Source:

FAQ

What insider trades occurred at GSK on June 20, 2025?

Multiple GSK directors purchased shares on June 20, 2025, including Charles Bancroft (2,021 ADSs at $37.8958), Lady Susan Symonds (1,350 Ordinary Shares at 拢14.3550), and several other directors who purchased between 257-889 ADSs at $37.8958 each.

How much did GSK stock cost in USD and GBP on June 20, 2025?

On June 20, 2025, GSK's American Depositary Shares (ADSs) traded at $37.8958 on the NYSE, while Ordinary Shares traded at 拢14.3550 on the London Stock Exchange.

Who is the largest insider purchaser of GSK stock in the June 2025 transactions?

Charles Bancroft, GSK's Senior Independent Non-Executive Director, made the largest purchase with 2,021 American Depositary Shares at $37.8958 per share.

How many GSK directors purchased American Depositary Shares in June 2025?

Seven GSK directors purchased American Depositary Shares in June 2025: Elizabeth Anderson, Charles Bancroft, Hal Barron, Anne Beal, Hal Dietz, Jeannie Lee, and Vishal Sikka.

What is the total value of GSK shares purchased by Charles Bancroft in June 2025?

Charles Bancroft purchased 2,021 ADSs at $37.8958 per share, for a total investment of approximately $76,587.71.
Stock GSK logo
GSK PLC

NYSE:GSK

GSK Rankings

#219 Ranked by Market Cap
#701 Ranked by Dividends

GSK Latest News

Jul 27, 2025
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Jul 24, 2025
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
Jul 17, 2025
US FDA Approves GSK鈥檚 SHINGRIX in a Prefilled Syringe Presentation
Jul 10, 2025
GSK begins shipping influenza vaccine doses for the 2025-26 flu season
Jun 24, 2025
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

GSK Latest SEC Filings

Jul 29, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 28, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 25, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 24, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)
Jul 24, 2025
[6-K] GSK plc American Current Report (Foreign Issuer)

GSK Stock Data

76.65B
2.04B
0.06%
17.05%
0.91%
Drug Manufacturers - General
Healthcare
United Kingdom
England